Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4451363
  • Report
  • 107 pages
  • P&S Market Research
1 of 3
IL-6 inhibitors currently exhibits a growing pipeline with approximately 18 active drug candidates.

IL-6 inhibitors therapeutics pipeline in 2017

The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis.

Insights on pipeline segments

According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody.

Positive Clinical Results of IL-6 Inhibitors Therapeutics Candidates

The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo.

Various collaborations for IL-6 Inhibitors therapeutics drug development

In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales.

Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others.

IL-6 Inhibitors Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis by Phase (2017)
5.1 Filed: Drug profiles
5.1.3 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase III: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
Phase I: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.4 Pre-Clinical: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology
5.5 Discovery: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for IL-6 Inhibitors Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for IL-6 Inhibitors Therapeutics Pipeline

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for IL-6 Inhibitors Therapeutics Pipeline
7.2 SWOT Analysis of IL-6 Inhibitors Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Il-6 Inhibitors Therapeutics, By Company (2017)
Description Of Filed Drug Candidates
Clinical Trials Of Filed Drug Candidates
Description Of Phase III Drug Candidates
Clinical Trials Of Phase III Drug Candidates
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Companies- at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Il-6 Inhibitors Therapeutics Drug Candidates Under Development (2017)
Il-6 Inhibitors Therapeutics Pipeline Split, By Molecule Type (2017)
Il-6 Inhibitors Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll